Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
haploidentical NK cells + talazoparib
- Development stage
- Unknown
- Lead developer
- German Cancer Research Center
- Modality
- Small Molecules, CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous, Oral
01
Overview
This investigational combination immunotherapy consists of adoptively transferred haploidentical allogeneic natural killer (NK) cells and the PARP inhibitor talazoparib. Developed by the German Cancer Research Center (DKFZ), the therapy is specifically designed to target leukemic stem cells (LSCs) in patients with acute myeloid leukemia (AML). The mechanism involves talazoparib-induced upregulation of NKG2D ligands on LSCs, which are typically downregulated as an immune evasion tactic. This sensitization makes the LSCs susceptible to elimination by the infused allogeneic NK cells. The treatment is currently being evaluated in the Phase I/II NAKIP-AML trial for patients with relapsed/refractory or minimal residual disease (MRD)-positive AML.
- Other names
- NK cells + talazopariballogeneic NK cells + talazoparib
02
Targets
NKG2D (Natural killer group 2 member D receptor)
Beyond the preview
Go deeper on haploidentical NK cells + talazoparib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on haploidentical NK cells + talazoparib.